Document is current
Any future updates will be listed below
-
Authors
Baribeau, Danielle A.
Dupuis, Annie
Paton, Tara A.
Hammill, Christopher
Scherer, Stephen W.
Schachar, Russell J.
Arnold, Paul D.
Szatmari, Peter
Nicolson, Rob
Georgiades, Stelios
Crosbie, Jennifer
Brian, Jessica
Iaboni, Alana
Kushki, Azadeh
Lerch, Jason P.
Anagnostou, Evdokia
-
Funding
Funding for this research was provided by:
American Academy of Child and Adolescent Psychiatry
Ontario Brain Institute (IDS-I l-02, IDS-I l-02, IDS-I l-02, IDS-I l-02, IDS-I l-02, IDS-I l-02, IDS-I l-02, IDS-I l-02, IDS-I l-02, IDS-I l-02, IDS-I l-02, IDS-I l-02, IDS-I l-02, IDS-I l-02, IDS-I l-02, IDS-I l-02)
- License Information
-
More Information
Article History
Received: 27 July 2018
Revised: 21 November 2018
Accepted: 1 January 2019
First Online: 4 February 2019
Competing interests
: R.J.S. has consulted to Highland Therapeutics, Eli Lilly and Co., and Purdue Pharma. He has commercial interest in a cognitive rehabilitation software company, “eHave.” P.D.A. holds a patent for “SLCIAI Marker for Anxiety Disorder” granted 6 May 2008. P.S. has received royalties from Guilford Press. E.A. has served as a consultant to Roche. She has received grant funding from SanofiCanada and SynapDx. She has received royalties from APPI and Springer. E.A. and A.K. hold a provisional patent for the device, “Anxiety Meter.” S.W.S. is an academic scientific consultant advising or is in licensing arrangements with Athena, Diagnostics, King Abdulaziz University Lineagen, Deep Genomics and Population Diagnostics. He also holds the CIHR-GlaxoSmithKline Endowed Chair in Genome Sciences at the Hospital for Sick Children and University of Toronto. The remaining authors declare no competing interests.
